STAT3 and neoplasm: Ziegler (2018), using a STAT3 loss-of-function approach in two models of intestinal tumorigenesis, demonstrated that STAT3 targeting reduced colorectal carcinogenesis by increasing mitophagy and MHC class I antigen presentation in intestinal epithelial cells, which increased anti-tumor immunity through increased activation of CD8+ T cells [60].